Enhanced tumor visualization by gamma-scintigraphy with In-111-labeled polychelating-polymer-containing immunoliposomes

Erdogan S. , Roby A., Torchilin V. P.

MOLECULAR PHARMACEUTICS, vol.3, no.5, pp.525-530, 2006 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 3 Issue: 5
  • Publication Date: 2006
  • Doi Number: 10.1021/mp060055t
  • Page Numbers: pp.525-530
  • Keywords: tumor imaging, gamma-scintigraphy, In-111, polychelating amphiphilic polymer, liposome, monoclonal antibody 2C5, CONTRAST AGENTS, IMAGING AGENTS, LIPOSOMES, DELIVERY, ANTIBODIES, CELLS, MODEL, MRI


Here, we have prepared long-circulating PEGylated liposomes heavily loaded with In-111 via the liposome-incorporated polylysine-based (PLL-based) polychelating amphiphilic polymer (PAP) and additionally modified with the monoclonal antibody 2C5 (mAb 2C5) possessing the nucleosome-restricted (NS-restricted) specificity and capable of specific recognition of a broad variety of live cancer cells via the cancer cell surface bound NSs. These liposomes have been tested as a tumor-specific contrast agent for the gamma-scintigraphic visualization of model tumors in mice. The tumor accumulation of mAb 2C5 modified liposomes prepared in this study was significantly (3-to-5-fold) higher than in the neighboring muscle tissue at all times after administration (6, 24, and 48 h) in mice bearing murine Lewis lung carcinoma (LLC) and human HT-29 tumors. The whole body direct gamma-imaging of LLC tumor bearing mice at different times has demonstrated the superior in vivo tumor accumulation of the targeted mAb 2C5 modified PAP-containing PEGylated liposomes compared to nontargeted liposomal control formulations, which resulted in better and faster tumor imaging as shown with LLC-bearing mice.